A Phase 2b Randomized, Double-Masked, Sham-Controlled, Study to Evaluate the Efficacy and Safety of Intravitreal Injection of MCO-010 Optogenetic Therapy in Adults With Retinitis Pigmentosa [RESTORE]

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Aug 2024

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Jul 2024 Results published in a Nanoscope Therapeutics Media Release
10 Jul 2024 According to a Nanoscope Therapeutics Media Release, first time 100-week topline results from this trial to be presented in a presentation by Dr. Michael Singer, Clinical Professor of Ophthalmology at the University of Texas Health Science Center, at the 2024 ASRS Annual Scientific Meeting taking place from July 17-July 20, 2024 at the Stockholmsmassan Convention Center in Stockholm, Sweden.
07 May 2024 According to a Nanoscope Therapeutics Media Release, data from this study will be presented at 2024 American Society of Gene + Cell Therapy (ASGCT) Annual Meeting and Retina World Congress being held in Baltimore, Maryland and Fort Lauderdale, Florida,on May 8 and 10 respectively.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com